EAM
DYN icon

Exome Asset Management’s Dyne Therapeutics DYN Stock Holding History

Exome Asset Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-195,933
Closed -$1.87M – 81
2025
Q2 		$1.87M Sell
195,933
-62,458
-24% -$688K 1.39% 31
2025
Q1 		$2.7M Buy
+258,391
New +$3.7M 2.4% 18

Other funds holding DYN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Exome Asset Management's DYN Position: Q3 2025 in Review

Exome Asset Management sold out of Dyne Therapeutics (DYN) in Q3 2025, closing a stake of 195,933 shares — an estimated $1.87M sold.

Exome Asset Management first reported a position in DYN in Q1 2025 and held it in 2 quarters. The position peaked at $2.7M in Q1 2025. 207 funds tracked by Wall St. Rank hold DYN as of Q3 2025.

  • Exome Asset Management reported no remaining Dyne Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Exome Asset Management sold 195,933 Dyne Therapeutics shares in Q3 2025, an estimated $1.87M.
  • Exome Asset Management first reported a position in Dyne Therapeutics in Q1 2025 and held it in 2 quarters.
  • Exome Asset Management's Dyne Therapeutics position peaked at $2.7M in Q1 2025.
  • 207 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2025.

Based on Exome Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.